Fairvalue-Calculator Fairvalue-Calculator
EN DE

NovaBridge Biosciences, a biotechnology company, (NBP) Fair Value & Analysis

Healthcare · US · Market cap $173M

Price$1.61
Fair Value$1.28
Upside-20.5%
Quality95/100
Evidence: Low Range $0.9600 – $1.61

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

NovaBridge Biosciences, a biotechnology company, (NBP) currently trades at $1.61, while our model-based Fair Value estimate is $1.28 — implying the stock looks roughly 20.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb fo…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is NovaBridge Biosciences, a biotechnology company, (NBP) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $1.28 versus a price of $1.61 — about −20% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NBP?
Our 21-model fair value for NovaBridge Biosciences, a biotechnology company, is $1.28 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.61.
What is the quality score of NBP?
NovaBridge Biosciences, a biotechnology company, has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.